Key Documents

View All Documentation

SML2104

Ambrisentan

Name: Ambrisentan
Brand: SIGMA

≥98% (HPLC), Endothelin ETA Receptor Antagonist, powder

Synonym(s):

(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₂H₂₂N₂O₄

CAS Number:

177036-94-1

Molecular Weight:

378.42

NACRES:

NA.77

UNSPSC Code:

41121706

MDL number:

MFCD08672619

Assay:

≥98% (HPLC)

Form:

powder

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Ambrisentan, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +160 to +190°, c = 0.5 in methanol

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CC1=CC(C)=NC(O[C@@H](C(C2=CC=CC=C2)(OC)C3=CC=CC=C3)C(O)=O)=N1

InChI

1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)

InChI key

OUJTZYPIHDYQMC-UHFFFAOYSA-N

Description

Biochem/physiol Actions

Ambrisentan is an endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It is 200-fold selective for the the ETA receptor subtype with a Ki of 1 nM for ETA and a Ki of 195 nM for ETB.

Endothelin ETA Receptor Antagonist; Antihypertensive; Pulmonary Hypertension Treatment

Still not finding the right product?

Explore all of our products under Ambrisentan

pictograms

GHS08

signalword

Danger

hcodes

H360FD

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 1A

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ambrisentan: a review of its use in pulmonary arterial hypertension.

Belinda N Rivera-Lebron et al.

Therapeutic advances in respiratory disease, 11(6), 233-244 (2017-04-21)

Pulmonary arterial hypertension (PAH) is a progressive disease defined by an elevation in pulmonary arterial pressure that can lead to right heart failure and death. Ambrisentan is a selective endothelin receptor antagonist approved for the treatment of idiopathic, heritable PAH

Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro.

Johanna Weiss et al.

European journal of pharmacology, 660(2-3), 298-304 (2011-04-20)

The safety and effectiveness of drugs used to treat chronic diseases critically depend on their propensity to interact with co-administered drugs. Induction of enzymes and drug transporters involved in the clearance and distribution of drugs may critically reduce exposure with

Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK.

Ilenia Masi et al.

Cell reports, 34(9), 108800-108800 (2021-03-04)

Cancer cells use actin-based membrane protrusions, invadopodia, to degrade stroma and invade. In serous ovarian cancer (SOC), the endothelin A receptor (ETAR) drives invadopodia by a not fully explored coordinated function of β-arrestin1 (β-arr1). Here, we report that β-arr1 links

View All Related Papers